Regimen deemed ‘safe and feasible’ in MM

Print Friendly, PDF & Email


Keren Osman, MD
A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018 BMT Tandem Meetings. Researchers conducted a phase 1 trial investigating the addition of elotuzumab and autologous peripheral blood mononuclear cell (PBMC) reconstitution to standard autologous hematopoietic stem cell transplant... [Read Article]
Print Friendly, PDF & Email

Cognitive impairment in HSCT recipients

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
New research suggests the risk of cognitive impairment after hematopoietic stem cell transplant (HSCT) is greatest among recipients of myeloablative allogeneic (allo) HSCTs. Compared to healthy controls, patients who received myeloablative allo-HSCT had a significantly higher risk of global cognitive deficit at a few time points after transplant.... [Read Article]
Print Friendly, PDF & Email

JAK2 inhibition could reduce risk of GVHD

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Preclinical research suggests that targeting JAK2 can reduce the risk of graft-versus-host disease (GVHD) in transplant recipients. Researchers found that genetic ablation of JAK2 on donor T cells or inhibition of JAK2 via treatment with pacritinib reduced GVHD in mice without compromising graft-versus-leukemia (GVL) activity. “An... [Read Article]
Print Friendly, PDF & Email

Agent can decrease GI toxicity in MM patients

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Results of a case-control study suggest a cytoprotective agent can reduce treatment-related gastrointestinal (GI) toxicity in patients with multiple myeloma (MM). Use of this agent, amifostine, was associated with significantly lower rates of grade 2 or higher oral mucositis, nausea, vomiting, and diarrhea. Additionally, amifostine did not... [Read Article]
Print Friendly, PDF & Email

FDA investigating VTEs related to ECP

Print Friendly, PDF & Email


Red and white blood cells
The US Food and Drug Administration (FDA) says it is evaluating reports of venous thromboembolism (VTE) in patients treated with the CELLEX Photopheresis System by Therakos, Inc. This extracorporeal photopheresis (ECP) device system is FDA-approved for use in patients with cutaneous T-cell lymphoma (CTCL). The system is used... [Read Article]
Print Friendly, PDF & Email

Adjunct to HSCT receives orphan designation

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
The European Commission (EC) has granted orphan designation to NLA101 as an adjunct to hematopoietic stem cell transplant (HSCT). NLA101 is a universal, off-the-shelf, stem and progenitor cell therapy intended to provide a short-term bridge for hematopoietic recovery while also providing long-term immunologic and clinical benefits in... [Read Article]
Print Friendly, PDF & Email

HLF proves ‘critical’ for HSC quiescence

Print Friendly, PDF & Email


HSCs in the bone marrow
Preclinical research suggests hepatic leukemia factor (HLF) protects hematopoietic stem cells (HSCs) by helping them maintain quiescence. Researchers found that HLF-deficient HSCs were more sensitive than wild-type HSCs to chemotherapy and irradiation. After transplantation in mice, HLF-deficient HSCs were less able than wild-type HSCs to reconstitute hematopoiesis. These findings... [Read Article]
Print Friendly, PDF & Email

Antiviral receives breakthrough designation for CMV

Print Friendly, PDF & Email


Micrograph showing
CMV infection
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to maribavir (SHP620) as a treatment for cytomegalovirus (CMV) infection and disease in transplant recipients who are resistant or refractory to prior therapy. Maribavir, an antiviral therapy that belongs to a class of drugs called benzimidazole ribosides,... [Read Article]
Print Friendly, PDF & Email